Drug Type Vaccine |
Synonyms Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.GagPol + Ad26.Mos2.GagPol, Ad26.Mos4.HIV, Adenovirus serotype26 mosaic4 HIV vaccine + [4] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | US | 31 Oct 2019 | |
HIV Infections | Phase 3 | AR | 31 Oct 2019 | |
HIV Infections | Phase 3 | BR | 31 Oct 2019 | |
HIV Infections | Phase 3 | IT | 31 Oct 2019 | |
HIV Infections | Phase 3 | MX | 31 Oct 2019 | |
HIV Infections | Phase 3 | PE | 31 Oct 2019 | |
HIV Infections | Phase 3 | PL | 31 Oct 2019 | |
HIV Infections | Phase 3 | PR | 31 Oct 2019 | |
HIV Infections | Phase 3 | ES | 31 Oct 2019 |
Phase 1/2 | - | 201 | (Tetravalent Ad26.Mos4.HIV Vaccine) | itxybhqhnm(vjewwteusj) = auhijqyrfc wnsqrwutlf (weaewwgbxk, gjscmyhwix - nwwsgdufkk) View more | - | 09 Jun 2023 | |
Ad26.Mos.HIV Vaccine (Trivalent Ad26.Mos.HIV Vaccine) | itxybhqhnm(vjewwteusj) = wniykdydtn wnsqrwutlf (weaewwgbxk, dhgmpoylvk - devplpugjg) View more | ||||||
Phase 2 | 2,636 | Ad26.Mos.HIV Vaccine (Group 1: Ad26.Mos.HIV Vaccine) | iitryybfcb(ueylmeqlxu) = tgrpqdwkri uvqwbffzwk (eclizblmsz, nmyaptnkqf - ewvmlynjof) View more | - | 18 Apr 2023 | ||
Placebo+Ad26.Mos4.HIV (Group 2: Placebo) | iitryybfcb(ueylmeqlxu) = mhybvzubos uvqwbffzwk (eclizblmsz, hmgptvtghi - hnshtfgfbb) View more |